We welcome the focus that is being given to health outcomes and patient experience. As medicines form an integral part of treatment pathways and are proven to be an investment to improved outcomes and better patient satisfaction, a national outcome measure linked to the uptake of innovative medicines should be adopted.
NHS Commissioning Board
Given the important decisions the NHS Commissioning Board will need to make, it is imperative to ensure that all significant stakeholders in the provision of health to patients are adequately represented on this Board and to ensure "holistic" commissioning. This Board should include representatives from the pharmaceutical industry and other life science industries as they provide key components of treatments in all priority areas of commissioning.
The pharmaceutical industry has evolved and adapted to changes in the environment and so can provide useful change management skills that will be crucial in the delivery of changes within the health system outlined in the White Paper, in terms of structure, process and in behaviours. The decision- making pathway will require as much transparency as possible on processes and so procedures to be followed should be agreed with partners, consulted on and published.
Download the ABPI response to the Government’s consultation on Commissioning (PDF, 586KB)